Pacira Pharmaceuticals buy Barclays PLC
Start price
08.05.24
/
50%
€26.80
Target price
08.05.25
€35.35
Performance (%)
-52.99%
Price
22.08.24
€12.30
Summary
This prediction is currently active. The BUY prediction by Barclays_PLC for Pacira Pharmaceuticals is performing very badly with a performance of -52.99%. This prediction currently runs until 08.05.25. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 6.957% | 6.957% |
iShares Core DAX® | 1.665% | 0.362% |
iShares Nasdaq 100 | -0.475% | -3.195% |
iShares Nikkei 225® | 2.620% | 1.174% |
iShares S&P 500 | -0.091% | -1.597% |
Comments by Barclays_PLC for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $40.00 to $38.00. They now have an "overweight" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Barclays_PLC for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.20
23.10.23
23.10.23
€53.51
23.10.24
23.10.24
-53.05%
22.08.24
22.08.24